Company Description
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therap...
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Valuation
P/E Current
5.04
P/E Ratio (with extraordinary items)
4.16
P/E Ratio (without extraordinary items)
8.97
Price to Sales Ratio
5.95
Price to Book Ratio
7.24
Price to Cash Flow Ratio
8.05
Enterprise Value to EBITDA
3.49
Enterprise Value to Sales
2.09
Efficiency
Total Asset Turnover
1.14
Liquidity
Current Ratio
1.76
Quick Ratio
1.60
Cash Ratio
1.18
Profitability
Gross Margin
84.53
Operating Margin
71.89
Pretax Margin
72.15
Net Margin
66.27
Return on Assets
75.78
Return on Equity
146.08
Return on Total Capital
148.24
Capital Structure
Total Debt to Total Assets
3.68
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Mr. Stéphane Bancel | 48 | - | President, Founding CEO & Director |
Dr. Stephen Hoge | 45 | - | SVP-Corporate Development & New Drug Concepts |
Mr. David W. Meline | 63 | 2022 | Chief Financial Officer |
Dr. Paul Burton | 52 | 2021 | Chief Medical Officer |
Mr. Juan Andres | 56 | 2017 | Chief Technical Operations & Quality Officer |
Insider Actions
06/16/2022 |
Stéphane Bancel Chief Executive Officer; Director |
10,000 | Disposition at $124.29 per share. | 1,242,900 |
06/16/2022 |
Stéphane Bancel Chief Executive Officer; Director |
11,195 | Disposition at $120.69 per share. | 1,351,124 |
06/16/2022 |
Stéphane Bancel Chief Executive Officer; Director |
15,005 | Disposition at $119.85 per share. | 1,798,349 |
06/16/2022 |
Stéphane Bancel Chief Executive Officer; Director |
13,800 | Disposition at $119.16 per share. | 1,644,408 |
06/16/2022 |
Stéphane Bancel Chief Executive Officer; Director |
40,000 | Derivative/Non-derivative trans. at $0.99 per share. | 39,600 |
06/15/2022 |
Stéphane Bancel Chief Executive Officer; Director |
2,800 | Disposition at $130.63 per share. | 365,764 |
06/15/2022 |
Stéphane Bancel Chief Executive Officer; Director |
9,206 | Disposition at $129.87 per share. | 1,195,583 |
06/15/2022 |
Stéphane Bancel Chief Executive Officer; Director |
9,451 | Disposition at $128.84 per share. | 1,217,666 |
06/15/2022 |
Stéphane Bancel Chief Executive Officer; Director |
6,225 | Disposition at $127.88 per share. | 796,053 |
06/15/2022 |
Stéphane Bancel Chief Executive Officer; Director |
4,279 | Disposition at $126.75 per share. | 542,363 |
06/15/2022 |
Stéphane Bancel Chief Executive Officer; Director |
5,659 | Disposition at $125.87 per share. | 712,298 |
06/15/2022 |
Stéphane Bancel Chief Executive Officer; Director |
2,380 | Disposition at $124.63 per share. | 296,619 |
06/15/2022 |
Stéphane Bancel Chief Executive Officer; Director |
40,000 | Derivative/Non-derivative trans. at $0.99 per share. | 39,600 |
06/13/2022 |
Stephen Hoge President |
10,000 | Disposition at $123 per share. | 1,230,000 |
06/13/2022 |
Stephen Hoge President |
5,000 | Derivative/Non-derivative trans. at $10.9 per share. | 54,500 |
06/13/2022 |
Stephen Hoge President |
5,000 | Derivative/Non-derivative trans. at $10.9 per share. | 54,500 |
06/09/2022 |
Stéphane Bancel Chief Executive Officer; Director |
10,000 | Disposition at $148.07 per share. | 1,480,700 |
06/09/2022 |
Stéphane Bancel Chief Executive Officer; Director |
1,605 | Disposition at $141.79 per share. | 227,572 |
06/09/2022 |
Stéphane Bancel Chief Executive Officer; Director |
2,871 | Disposition at $140.85 per share. | 404,380 |
06/09/2022 |
Stéphane Bancel Chief Executive Officer; Director |
1,483 | Disposition at $139.61 per share. | 207,041 |
06/09/2022 |
Stéphane Bancel Chief Executive Officer; Director |
2,155 | Disposition at $138.58 per share. | 298,639 |
06/09/2022 |
Stéphane Bancel Chief Executive Officer; Director |
10,458 | Disposition at $137.58 per share. | 1,438,811 |
06/09/2022 |
Stéphane Bancel Chief Executive Officer; Director |
12,629 | Disposition at $136.71 per share. | 1,726,510 |
06/09/2022 |
Stéphane Bancel Chief Executive Officer; Director |
7,517 | Disposition at $135.6 per share. | 1,019,305 |
06/09/2022 |
Stéphane Bancel Chief Executive Officer; Director |
1,282 | Disposition at $134.68 per share. | 172,659 |
06/09/2022 |
Stéphane Bancel Chief Executive Officer; Director |
40,000 | Derivative/Non-derivative trans. at $0.99 per share. | 39,600 |
06/08/2022 |
Stéphane Bancel Chief Executive Officer; Director |
6,700 | Disposition at $151.39 per share. | 1,014,313 |
06/08/2022 |
Stéphane Bancel Chief Executive Officer; Director |
3,328 | Disposition at $150.75 per share. | 501,696 |
06/08/2022 |
Stéphane Bancel Chief Executive Officer; Director |
15,972 | Disposition at $149.94 per share. | 2,394,841 |
06/08/2022 |
Stéphane Bancel Chief Executive Officer; Director |
14,000 | Disposition at $148.19 per share. | 2,074,660 |
06/08/2022 |
Juan Andres See remarks |
10,000 | Disposition at $150 per share. | 1,500,000 |
06/08/2022 |
Shannon Thyme Klinger Chief Legal Officer |
1,265 | Disposition at $148.12 per share. | 187,371 |
06/08/2022 |
Stéphane Bancel Chief Executive Officer; Director |
40,000 | Derivative/Non-derivative trans. at $0.99 per share. | 39,600 |
06/08/2022 |
Juan Andres See remarks |
629 | Derivative/Non-derivative trans. at $14.22 per share. | 8,944 |
06/08/2022 |
Juan Andres See remarks |
2,000 | Derivative/Non-derivative trans. at $20.93 per share. | 41,860 |
06/08/2022 |
Juan Andres See remarks |
2,000 | Derivative/Non-derivative trans. at $20.93 per share. | 41,860 |
06/08/2022 |
Juan Andres See remarks |
2,000 | Derivative/Non-derivative trans. at $20.93 per share. | 41,860 |
06/08/2022 |
Juan Andres See remarks |
2,000 | Derivative/Non-derivative trans. at $20.93 per share. | 41,860 |
06/08/2022 |
Juan Andres See remarks |
1,371 | Derivative/Non-derivative trans. at $20.93 per share. | 28,695 |
06/07/2022 |
Shannon Thyme Klinger Chief Legal Officer |
4,554 | Derivative/Non-derivative trans. at $140 per share. | 637,560 |
06/02/2022 |
Stéphane Bancel Chief Executive Officer; Director |
10,000 | Disposition at $140 per share. | 1,400,000 |
06/02/2022 |
Stéphane Bancel Chief Executive Officer; Director |
6,500 | Disposition at $139.79 per share. | 908,635 |
06/02/2022 |
Stéphane Bancel Chief Executive Officer; Director |
14,000 | Disposition at $138.58 per share. | 1,940,120 |
06/02/2022 |
Stéphane Bancel Chief Executive Officer; Director |
300 | Disposition at $136.72 per share. | 41,016 |
06/02/2022 |
Stéphane Bancel Chief Executive Officer; Director |
7,000 | Disposition at $135.12 per share. | 945,840 |
06/02/2022 |
Stéphane Bancel Chief Executive Officer; Director |
10,100 | Disposition at $134.06 per share. | 1,354,006 |
06/02/2022 |
Stéphane Bancel Chief Executive Officer; Director |
900 | Disposition at $132.68 per share. | 119,412 |
06/02/2022 |
Stéphane Bancel Chief Executive Officer; Director |
1,200 | Disposition at $131.56 per share. | 157,872 |
06/02/2022 |
Stéphane Bancel Chief Executive Officer; Director |
40,000 | Derivative/Non-derivative trans. at $0.99 per share. | 39,600 |
06/01/2022 |
Stéphane Bancel Chief Executive Officer; Director |
400 | Disposition at $148.44 per share. | 59,376 |
06/01/2022 |
Stéphane Bancel Chief Executive Officer; Director |
800 | Disposition at $147.46 per share. | 117,968 |
06/01/2022 |
Stéphane Bancel Chief Executive Officer; Director |
1,063 | Disposition at $146.65 per share. | 155,888 |
06/01/2022 |
Stéphane Bancel Chief Executive Officer; Director |
4,137 | Disposition at $145.62 per share. | 602,429 |
06/01/2022 |
Stéphane Bancel Chief Executive Officer; Director |
5,329 | Disposition at $144.33 per share. | 769,134 |
06/01/2022 |
Stéphane Bancel Chief Executive Officer; Director |
12,049 | Disposition at $143.58 per share. | 1,729,995 |
06/01/2022 |
Stéphane Bancel Chief Executive Officer; Director |
13,056 | Disposition at $142.51 per share. | 1,860,610 |
06/01/2022 |
Stéphane Bancel Chief Executive Officer; Director |
3,166 | Disposition at $141.67 per share. | 448,527 |
06/01/2022 |
Stéphane Bancel Chief Executive Officer; Director |
40,000 | Derivative/Non-derivative trans. at $0.99 per share. | 39,600 |
05/31/2022 |
Stephen Hoge President |
7,431 | Disposition at $144.97 per share. | 1,077,272 |
05/31/2022 |
Stephen Hoge President |
999 | Disposition at $145.4 per share. | 145,254 |
05/31/2022 |
Juan Andres See remarks |
749 | Disposition at $145.4 per share. | 108,904 |
05/31/2022 |
Stephen Hoge President |
7,431 | Derivative/Non-derivative trans. at $0.99 per share. | 7,356 |
05/27/2022 |
Stephen Hoge President |
2,410 | Derivative/Non-derivative trans. at $135.8 per share. | 327,278 |
05/27/2022 |
Juan Andres See remarks |
1,807 | Derivative/Non-derivative trans. at $135.8 per share. | 245,390 |
MarketWatch News on MRNA
-
Moderna Inc. stock outperforms competitors on strong trading day
- MarketWatch Automation
-
FDA Asks for Fall Boosters to Target BA.5
- Josh Nathan-Kazis
-
FDA Asks Vaccine Makers for Boosters to Target BA.5
- Josh Nathan-Kazis
-
Pfizer Raises Covid Vaccine Price 27%. What It Means for the Stock.
- Josh Nathan-Kazis
-
Moderna Inc. stock rises Wednesday, outperforms market
- MarketWatch Automation
-
FDA Advisers Sign Off on Omicron Booster
- Josh Nathan-Kazis
-
Moderna Inc. stock outperforms market despite losses on the day
- MarketWatch Automation
-
J&J does not plan to update its COVID-19 vaccine
- Jaimy Lee
-
Moderna Inc. stock outperforms market on strong trading day
- MarketWatch Automation
-
FDA Panel Will Weigh In on Covid Boosters for This Fall
- Josh Nathan-Kazis
-
COVID vaccines for kids under 5 — what parents need to know
- Nicole Lyn Pesce
- Loading more headlines...
Other News on MRNA
-
FDA Directs Drug Makers on Fall Covid-19 Boosters
- Peter Loftus
-
Could This Send Moderna's Stock Soaring Back to $400?
- Motley Fool
-
- Motley Fool
-
3 Things About Moderna That Smart Investors Know
- Motley Fool
-
Greenblatt's Magic Formula For Beating The Market
- Seeking Alpha
-
Healthcare Sector Stock Performance Continues To Improve
- Seeking Alpha
-
U.S. Agrees to Pay $3.2 Billion for More Pfizer Covid Vaccines
- Andrew Restuccia
-
2 Dividend Stocks With Huge Passive Income Potential
- Motley Fool
-
FDA targets updated COVID-19 vaccines for adults by October
- Seeking Alpha
-
The 3 Smartest Real Estate Stocks to Buy Right Now
- Motley Fool
- Loading more headlines...